What is the Methotrexate drug?
Methotrexate was first known under the name amethopterin. Methotrexate is an immune system suppressant and a chemotherapy agent. Methotrexate works by inhibiting enzymes that are responsible for nucleotide synthesis. By inhibiting those enzymes, Methotrexate suppresses the inflammation and intervenes in the growth and division of cells that quickly reproduce.
Methotrexate is a medication used to treat cancers, such as leukemia, lymphoma, osteosarcoma, breast cancer, lung cancer, and gestational trophoblastic disease. Methotrexate also acts on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Methotrexate is also used to treat ectopic pregnancy, and for medical abortions.
Methotrexate is a long-standing drug that has been in medical use since 1947 when it was the least toxic treatment for cancer diseases. In 1953, the FDA approved Methotrexate medical use.
Methotrexate is on the World Health Organization's List of Essential Medicines.
Methotrexate manufacturers and wholesalers:
Many Methotrexate patents will expire in 2030, however, some have already expired, and manufacturers could develop their products. For this reason, Methotrexate has various brand names, among them, we can list Abitrexate by Teva, Alltrex by Naprod, Artrait by TRB, Atrexel by Schering-Plough, Bendatrexat by Bendalis, Carditrex by Cadila, Ebetrex by Ebewe, Ledertrexate by Biodim, Maxtrex Pfizer, Meisusheng by Hospira, Rheumatrex by Wyeth KK, rexan by Atafarm, and Zexate by Dabur Pharma.
Methotrexate is produced by many manufacturers, such as Bristol Myers Squibb, Mylan Pharmaceuticals Inc, Norbrook Laboratories Ltd, Abic Ltd, Abraxis Pharmaceutical Products, Amneal Pharmaceuticals LLC, Roxane Laboratories, Inc, Sandoz Inc, Sun Pharmaceutical Industries Inc, Accord Healthcare Inc, AvKare, Inc, and Zydus Pharmaceuticals (USA) Inc, among others.
Methotrexate is marketed in the form of 2.5 mg oral tablets, 1 g/40 ml, 100 mg/4 ml, 200 mg/8 ml, 250 mg/10 ml, 50 mg/2 ml injectable solutions in prefilled syringes, prefilled pens, 25 mg/ml powder for injection when reconstituted, and vials.. as the safest and most effective drugs marketed as both trade name and generic medications by numerous suppliers worldwide, it remains one of the most common treatment choices for certain cancers.
Methotrexate for sales:
Methotrexate costs depend on the country it is sold in and the health policies of the country.
In the US, one gram Methotrexate injectable powder costs about $62.92 per unit. A 25 mg/ml Methotrexate injectable solution costs from $3.77 to $3.96 per unit. For a 2.5 mg tablet, Methotrexate costs from $0.74 to $2.69 per tablet.
As Methotrexate is a globally found drug, on the internet you can encounter fraudulent websites that will want to sell Methotrexate with some risks for you and your clients. By using Pipelinepharma B2B marketplace, you avoid time-consuming sourcing and you directly find qualified sellers of Methotrexate that have been through quality control procedures to assure they were qualified partners. On the online platform, Methotrexate is mostly available from the EU, Turkey, Canada, India, Switzerland, Argentina, Guatemala, and Indonesia. Thanks to the intuitive online marketplace, you will find Methotrexate and many other drugs quickly and efficiently. Placing an order or an inquiry has never been easier than with Pipelinepharma. Let us connect you with Methotrexate manufacturers wherever they are in the world. Not only is this marketplace good news for distributors and other buyers, but wholesale sellers and manufacturers benefit as well. They can register and list an unlimited number of pharmaceutical products free of charge.
How to use the Methotrexate drug?
To treat acute lymphoblastic leukemia, an adult patient should be administered the induction dose of 3.3 mg/m2/day orally or parenterally (in combination with prednisone 60 mg/m2) daily for 4 to 6 weeks. At the maintenance stage of the remission, the patient should be administered 30 mg/m2 of Methotrexate orally or IM twice a week.
To treat trophoblastic disease, an adult patient should be administered 15 mg to 30 mg of Methotrexate orally or by IM injection for a 5-day course; courses are usually repeated for 3 to 5 times, with rest periods of one or more weeks between courses, until any manifesting toxic symptoms subside.
To treat lymphoma, during the Burkitt's tumor Stages I to II, an adult patient should take 10 mg to 25 mg of Methotrexate orally once a day for 4 to 8 days, at the Burkitt's tumor Stage III, Methotrexate is usually given in combination with other antitumor agents. For Lymphosarcoma Stage III, an adult patient should be administered 0.625 to 2.5 mg/kg orally daily as a part of combination chemotherapy.
To treat meningeal leukemia, an adult patient should take 12 mg of Methotrexate intrathecally every 2 to 5 days.
To treat osteosarcoma, an adult patient should take the initial dose of 12 g/m2 IV as a 4-hour infusion (in combination with other chemotherapeutic agents). The dose can be increased to 15 15 g/m2; if this dose is not adequate to achieve a peak serum concentration of 1000 micromolar.
To treat psoriasis, an adult patient should take 10 mg to 25 mg per week orally, IM, IV, or subcutaneously until an adequate response is achieved in a single dose. The maximum dose is 30 mg per week.
To treat rheumatoid arthritis, an adult patient should take 7.5 mg of Methotrexate once a week in a single dose. The maximum dose is 20 mg per week.
Taking Methotrexate can cause some side effects, the most common ones are nausea, bloody vomit, diarrhea, feeling tired, fever, joint pain, increased risk of infection, low white blood cell counts, reddening of the skin, sores in the mouth or lips, stomach pain, swelling of the feet or lower legs.
During a Methotrexate therapy, it is recommended to avoid alcohol, milk and dairy products, and to limit caffeine intake.